RECURSION PHARMACEUTICALS, INC. (RXRX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -518.88M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-518.88M | (m) |
| 2026-03-31 | (m) | $-559.78M | (m) |
| 2025-12-31 | (m) | $-644.76M | (m) |
| 2025-09-30 | (m) | $-715.54M | (m) |
| 2025-06-30 | (m) | $-649.13M | (m) |
| 2025-03-31 | (m) | $-574.77M | (m) |
| 2024-12-31 | (m) | $-463.66M | (m) |
| 2024-09-30 | (m) | $-377.75M | (m) |
| 2024-06-30 | (m) | $-374.93M | (m) |
| 2024-03-31 | (m) | $-354.11M | (m) |
| 2023-12-31 | (m) | $-328.07M | (m) |
| 2023-09-30 | (m) | $-292.56M | (m) |
| 2023-06-30 | (m) | $-259.99M | (m) |
| 2023-03-31 | (m) | $-248.82M | (m) |
| 2022-12-31 | (m) | $-239.48M | (m) |
| 2022-09-30 | (m) | $-246.92M | (m) |
| 2022-06-30 | (m) | $-233.90M | (m) |
| 2022-03-31 | (m) | $-211.74M | (m) |
| 2021-12-31 | (m) | $-186.48M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-87.01M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | $-61.88M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |